Have a feature idea you'd love to see implemented?
Let us know!
BMRN Biomarin Pharmaceutical Inc
Price (delayed)
$70.39
Market cap
$13.4B
P/E Ratio
52.14
Dividend/share
N/A
EPS
$1.35
Enterprise value
$13.52B
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for serious and life-threatening rare and ultra-rare genetic diseases. The Company's portfolio consists of six commercialized products and
Highlights
Biomarin Pharmaceutical's EPS has surged by 160% YoY and by 24% QoQ
The net income has surged by 157% year-on-year and by 25% since the previous quarter
BMRN's quick ratio is down by 40% year-on-year but it is up by 15% since the previous quarter
Key stats
What are the main financial stats of BMRN
Market
Valuations
Earnings
Shares outstanding
190.38M
Market cap
$13.4B
Enterprise value
$13.52B
Price to earnings (P/E)
52.14
Price to book (P/B)
2.53
Price to sales (P/S)
5.17
EV/EBIT
42.82
EV/EBITDA
32.03
EV/Sales
5.22
Revenue
$2.59B
EBIT
$315.68M
EBITDA
$422.04M
Free cash flow
$240.78M
Per share
Balance sheet
Liquidity
EPS
$1.35
Free cash flow per share
$1.27
Book value per share
$27.84
Revenue per share
$13.61
TBVPS
$34.74
Total assets
$7.07B
Total liabilities
$1.78B
Debt
$1.09B
Equity
$5.29B
Working capital
$2.19B
Debt to equity
0.21
Current ratio
3.05
Quick ratio
1.79
Net debt/EBITDA
0.28
Margins
Efficiency
Dividend
EBITDA margin
16.3%
Gross margin
80.1%
Net margin
9.9%
Operating margin
9.6%
Return on assets
3.7%
Return on equity
5.1%
Return on invested capital
5.7%
Return on capital employed
5.3%
Return on sales
12.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BMRN stock price
How has the Biomarin Pharmaceutical stock price performed over time
Intraday
0.59%
1 week
1.32%
1 month
1.31%
1 year
-15.55%
YTD
-27%
QTD
0.14%
Financial performance
How have Biomarin Pharmaceutical's revenue and profit performed over time
Revenue
$2.59B
Gross profit
$2.07B
Operating income
$248.79M
Net income
$256.59M
Gross margin
80.1%
Net margin
9.9%
The net income has surged by 157% year-on-year and by 25% since the previous quarter
The operating income has surged by 146% year-on-year and by 28% since the previous quarter
The net margin has soared by 120% year-on-year and by 19% since the previous quarter
Biomarin Pharmaceutical's operating margin has soared by 113% YoY and by 23% from the previous quarter
Growth
What is Biomarin Pharmaceutical's growth rate over time
Valuation
What is Biomarin Pharmaceutical stock price valuation
P/E
52.14
P/B
2.53
P/S
5.17
EV/EBIT
42.82
EV/EBITDA
32.03
EV/Sales
5.22
Biomarin Pharmaceutical's EPS has surged by 160% YoY and by 24% QoQ
BMRN's P/E is 74% below its 5-year quarterly average of 202.4 and 43% below its last 4 quarters average of 91.1
The stock's price to book (P/B) is 33% less than its 5-year quarterly average of 3.8 and 23% less than its last 4 quarters average of 3.3
The equity has grown by 11% YoY and by 4.2% from the previous quarter
BMRN's price to sales (P/S) is 35% less than its 5-year quarterly average of 8.0 and 25% less than its last 4 quarters average of 6.9
The revenue has grown by 16% YoY and by 4.7% from the previous quarter
Efficiency
How efficient is Biomarin Pharmaceutical business performance
Biomarin Pharmaceutical's ROIC has soared by 159% YoY and by 27% from the previous quarter
The ROE has soared by 143% YoY and by 21% from the previous quarter
BMRN's return on assets has surged by 131% year-on-year and by 23% since the previous quarter
Biomarin Pharmaceutical's return on sales has surged by 122% YoY and by 18% QoQ
Dividends
What is BMRN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BMRN.
Financial health
How did Biomarin Pharmaceutical financials performed over time
BMRN's quick ratio is down by 40% year-on-year but it is up by 15% since the previous quarter
The company's current ratio fell by 38% YoY but it rose by 11% QoQ
The debt is 79% smaller than the equity
The equity has grown by 11% YoY and by 4.2% from the previous quarter
BMRN's debt to equity is down by 9% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.